The Drug Enforcement Administration published a final rule on May 4 assigning hexahydrocannabinol (HHC) its own specific Schedule I listing and drug code: 7220. The action formalizes the federal government’s position that HHC, a cannabinoid widely sold in smoke shops and gas stations across the country, is and always has been illegal under federal law.
What Changed
HHC had previously been controlled under drug code 7370, the general tetrahydrocannabinol classification. The new standalone listing gives HHC its own identity within the Controlled Substances Act, making enforcement actions more straightforward for federal prosecutors.
The DEA bypassed the standard public comment period, stating the rule is technical in nature and does not change HHC’s existing legal status. The agency’s position is that HHC was never legal, and the new drug code simply clarifies an existing classification.
“HHC does not occur naturally in the cannabis plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp,” Terrence Boos, chief of the DEA’s Drug and Chemical Evaluation Section, wrote in earlier agency correspondence that formed the basis for the rule.
The Legal Gray Area That Fueled a Market
HHC became one of the most popular alternative cannabinoids following the 2018 Farm Bill, which legalized hemp and its derivatives containing less than 0.3 percent delta-9 THC. Companies marketed HHC as a legal psychoactive cannabinoid derived from hemp, arguing that its distinct molecular structure placed it outside existing controlled substance classifications.
The result was a multimillion-dollar market. HHC appeared in vapes, gummies, tinctures, and pre-rolls sold in convenience stores, gas stations, and online retailers in states where recreational cannabis remains illegal. Consumers turned to HHC as an accessible alternative to delta-8 THC, which had already drawn regulatory scrutiny in multiple states.
“The DEA isn’t banning something new. They’re making it easier to enforce a ban they say was always in place.” — Cannabis attorney Rod Kight
Industry Response
Cannabis attorneys have raised questions about whether the rule will survive legal challenge. The core issue is whether the DEA has the authority to classify a cannabinoid as synthetic when some researchers argue HHC does occur in trace amounts in the cannabis plant.
Several hemp industry groups have flagged the lack of public comment as a procedural vulnerability. If challenged in court, the DEA would need to defend both its classification of HHC as synthetic and its decision to skip notice-and-comment rulemaking.
For companies still selling HHC products, the new drug code creates immediate practical risks. Federal enforcement agencies now have a cleaner legal pathway for seizures and prosecutions, even in states where HHC sales have operated openly.
The Bigger Picture
The HHC rule lands at a moment when the federal government is tightening its stance on hemp-derived cannabinoids across the board. The November 12 ban on intoxicating hemp products will restrict any finished product containing more than 0.4 milligrams of total THC per container. The 2026 National Drug Control Strategy, released the same day as the HHC rule, specifically targets unregulated psychoactive hemp derivatives.
Together, these actions signal a coordinated push to close the loopholes that allowed alternative cannabinoids to flourish after the 2018 Farm Bill. Delta-8 THC, THCP, THC-O, and now HHC have all faced either state-level bans or federal enforcement actions within the past two years.
For consumers seeking compliant products, the shrinking list of legal hemp-derived cannabinoids makes third-party testing and certificates of analysis more important than ever. Products containing only CBD, CBG, CBN, and other nonintoxicating cannabinoids remain unaffected by the HHC rule and the broader November ban.
What Comes Next
The HHC market will not vanish overnight. State-level enforcement varies widely, and many retailers continue to stock HHC products pending clearer guidance. But the new drug code removes the plausible deniability that many sellers relied on.
Companies with HHC inventory face a choice: liquidate stock before enforcement actions ramp up, reformulate products around compliant cannabinoids, or challenge the rule in federal court. Early indications suggest that at least one legal challenge is being prepared, though no filing has been announced.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
